Recent Updates
Recently added Catalysts
ALLO Positive Sentiment

Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Allogene Therapeutics reported positive momentum in its Phase 2 ALPHA3 program for 1L Large B-cell Lymphoma. The trial benefits from an expanding network and increased MRD screening, particularly in Asia-Pacific. An update on the ALPHA3 clinical trial is expected in mid-2027, with enrollment completion on the horizon.

Market Sentiment Analysis

POSITIVE FACTORS

  • Enrollment momentum in the ALPHA3 trial continues.
  • Increased MRD screening supports trial efforts.
  • Brisk enrollment observed in the Asia-Pacific region.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+191%
120-day peak, hindsight
Typical move
10.3%
average across 5 past catalysts
Cash runway
~37 mo
Low dilution risk
Lead asset
ALLO-715
Phase 1 · Relapsed/Refractory Multiple Myeloma

Full Press Release Details

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ALPHA3 Enrollment Momentum Continues, Supported by Expanding Trial Network, Increased MRD Screening, and Brisk Enrollment in Asia-Pacific Next ALPHA3 Clinical Update Anticipated in Mid-2027, with Trial Enrollment Completion

Frequently Asked Questions

What is the ALPHA3 program about?

The ALPHA3 program focuses on 1L Large B-cell Lymphoma.

When is the next update for the ALPHA3 trial?

The next clinical update is anticipated in mid-2027.

How is enrollment in the ALPHA3 trial progressing?

Enrollment is brisk, especially in the Asia-Pacific region.

What supports the ALPHA3 trial's enrollment?

An expanding trial network and increased MRD screening support enrollment.

ShareAdd on Google
Tags: ALLO Allogene Therapeutics ALPHA3 trial Large B-cell Lymphoma clinical trial MRD screening
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$424M liquidity · $11M/mo burn
~37 mo
Low dilution risk
Lead asset
ALLO-715Phase 1
Relapsed/Refractory Multiple Myeloma →

Catalyst track record

+191%
best trade around ALLO's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ALLO.

See every catalyst's timing & PoA →